Recorded Q2 Revenue of $23.2 Million, a 29% Increase Compared to Prior Year Period Signed Multiple New Business Agreements Spanning Clinical Trial...
Contracted Activities Touch Upon Broad Range of Societal’s Offerings from Clinical Trial Services to Formulation Development to cGMP Manufacturing Work...
Webcast Scheduled for Wednesday, August 10, 2022, at 4:30 p.m. Eastern...
Agreement Highlights Momentum in Onshoring of Contract Manufacturing Projects to U.S. from Sites Around the World...
Societal to Receive Greater Portion of Profit Sharing from Verapamil PM Product Sales Societal Awarded Potential New GMP Manufacturing Agreements for...
SAN DIEGO and GAINESVILLE, Ga., July 07, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and...
Japanese Biopharmaceutical Company Engages Societal for Formulation, Fill/Finish and Lyophilization Activities to Support Ongoing Clinical Development of...
SAN DIEGO and GAINESVILLE, Ga., May 19, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development...
Recorded Q1 Revenue of $21 Million; A 26% Increase Compared to Prior Year Period Signed Multiple New Business Agreements Spanning Early Stage Through...
Agreement Establishes Societal as Exclusive Supplier in Europe Through 2023...